Search

Displaying results 3071 - 3080 of 4539 in total
  1. Drug

    Elvitegravir

    go.drugbank.com/drugs/DB09101
    ApprovedInvestigational

    Elvitegravir was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences. It was FDA approved on August 27, 2012.

  2. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite.

  3. Drug

    Piperacillin

    go.drugbank.com/drugs/DB00319
    ApprovedInvestigational

    Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.

  4. Drug

    Oxacillin

    go.drugbank.com/drugs/DB00713
    ApprovedInvestigational

    An antibiotic similar to flucloxacillin used in resistant staphylococci infections.

  5. Drug

    Mezlocillin

    go.drugbank.com/drugs/DB00948
    Approved

    Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.

  6. Drug

    Rivoglitazone

    go.drugbank.com/drugs/DB09200
    Investigational

    It is being developed by Daiichi Sankyo Co.

  7. Drug

    Fosinoprilat

    go.drugbank.com/drugs/DB14207
    Experimental

    Fosinoprilat is the active phosphinic acid metabolite of prodrug [fosinopril], which is activated by esterases in vivo. It binds zinc with phosphinic acid group.

  8. Drug

    GLP-1 (7-36) amide

    go.drugbank.com/drugs/DB19258
    Investigational

    GLP-1 (7-36) amide is under investigation in clinical trial NCT01185119 (Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET).

  9. Drug

    AG0302-COVID19

    go.drugbank.com/drugs/DB16435
    Investigational

    Sponsored by Anges, Inc. in Japan, the AG0302-COVID19 is a DNA-based vaccine that recently completed Phase I/II trials (NCT04527081)[A226813, L30548].

  10. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]